Davidson Investment Advisors boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 8.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,053 shares of the medical research company’s stock after acquiring an additional 80 shares during the period. Davidson Investment Advisors’ holdings in Amgen were worth $257,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Regency Capital Management Inc. DE acquired a new position in Amgen in the first quarter valued at approximately $27,000. Maverick Capital Ltd. purchased a new stake in Amgen in the first quarter valued at approximately $27,000. Elmwood Wealth Management Inc. purchased a new stake in Amgen in the first quarter valued at approximately $31,000. Wolverine Asset Management LLC raised its position in Amgen by 1,587.5% in the first quarter. Wolverine Asset Management LLC now owns 135 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 127 shares during the period. Finally, KB Financial Partners LLC purchased a new stake in Amgen in the first quarter valued at approximately $35,000. Hedge funds and other institutional investors own 74.73% of the company’s stock.
NASDAQ:AMGN traded up $1.88 during mid-day trading on Wednesday, reaching $217.92. The stock had a trading volume of 12,788 shares, compared to its average volume of 2,587,297. Amgen Inc. has a twelve month low of $210.28 and a twelve month high of $276.69. The company has a debt-to-equity ratio of 3.45, a quick ratio of 1.03 and a current ratio of 1.31. The firm has a market capitalization of $123.75 billion, a price-to-earnings ratio of 21.98, a PEG ratio of 1.55 and a beta of 0.68. The business has a 50 day simple moving average of $232.74 and a 200 day simple moving average of $240.06.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 8th. Stockholders of record on Tuesday, August 17th were paid a dividend of $1.76 per share. The ex-dividend date of this dividend was Monday, August 16th. This represents a $7.04 dividend on an annualized basis and a dividend yield of 3.23%. Amgen’s dividend payout ratio (DPR) is 42.41%.
A number of analysts have issued reports on the company. Robert W. Baird reissued a “sell” rating on shares of Amgen in a research report on Thursday, August 5th. Zacks Investment Research raised Amgen from a “sell” rating to a “hold” rating and set a $255.00 price objective on the stock in a research report on Tuesday, June 29th. Mizuho began coverage on Amgen in a research report on Friday, September 10th. They set a “hold” rating and a $222.00 price objective on the stock. Morgan Stanley lowered Amgen from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $280.00 to $251.00 in a research report on Tuesday, September 7th. Finally, SVB Leerink cut their price objective on Amgen from $238.00 to $234.00 and set a “market perform” rating on the stock in a research report on Wednesday, August 4th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $249.70.
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.
Featured Story: What are the reasons investors use put options?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.